TrialRheumatology international2019

A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study.

Alexander M Lila et al.PubMed ↗Publisher ↗

No numbers read from the abstract.